1. Home
  2. CLW vs MDWD Comparison

CLW vs MDWD Comparison

Compare CLW & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Clearwater Paper Corporation

CLW

Clearwater Paper Corporation

HOLD

Current Price

$14.79

Market Cap

210.3M

ML Signal

HOLD

Logo MediWound Ltd.

MDWD

MediWound Ltd.

HOLD

Current Price

$16.92

Market Cap

193.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLW
MDWD
Founded
1926
2000
Country
United States
Israel
Employees
3710
N/A
Industry
Paper
Medicinal Chemicals and Botanical Products
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
210.3M
193.3M
IPO Year
2008
2013

Fundamental Metrics

Financial Performance
Metric
CLW
MDWD
Price
$14.79
$16.92
Analyst Decision
Buy
Strong Buy
Analyst Count
3
1
Target Price
$23.00
$36.00
AVG Volume (30 Days)
188.6K
81.7K
Earning Date
04-28-2026
05-20-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,555,400,000.00
N/A
Revenue This Year
N/A
$48.88
Revenue Next Year
$4.16
$35.08
P/E Ratio
N/A
N/A
Revenue Growth
12.42
N/A
52 Week Low
$12.46
$14.14
52 Week High
$30.96
$22.51

Technical Indicators

Market Signals
Indicator
CLW
MDWD
Relative Strength Index (RSI) 55.16 50.58
Support Level $12.46 $16.68
Resistance Level $18.85 $18.71
Average True Range (ATR) 0.67 0.77
MACD 0.28 -0.01
Stochastic Oscillator 91.95 70.87

Price Performance

Historical Comparison
CLW
MDWD

About CLW Clearwater Paper Corporation

Clearwater Paper Corp is engaged in the manufacturing and supplier of Solid Bleached Sulfate (SBS) paperboard packaging products. The company products includes: SBS paperboard which is a premium paperboard grade that is frequently used to produce folding cartons, food service, commercial printing items. It generates maximum revenue from Pulp and Paperboard segment. Company operate in United States and have globalized access too. Geographically, it derives maximum revenue from the United States.

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Share on Social Networks: